118 related articles for article (PubMed ID: 10762639)
1. Virulizin-2gamma, a novel immunotherapeutic agent, in treatment of human pancreatic cancer xenografts.
Liu C; Ferdinandi ES; Ely G; Joshi SS
Int J Oncol; 2000 May; 16(5):1015-20. PubMed ID: 10762639
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of Virulizin, a novel biological response modifier (BRM) in a panel of human pancreatic cancer and melanoma xenografts.
Feng N; Jin H; Wang M; Du C; Wright JA; Young AH
Cancer Chemother Pharmacol; 2003 Mar; 51(3):247-55. PubMed ID: 12655444
[TBL] [Abstract][Full Text] [Related]
3. Preclinical efficacy of Virulizin in human breast, ovarian and prostate tumor models.
Du C; Feng N; Jin H; Wang M; Wright JA; Young AH
Anticancer Drugs; 2003 Apr; 14(4):289-94. PubMed ID: 12679733
[TBL] [Abstract][Full Text] [Related]
4. Virulizin.
BioDrugs; 2002; 16(5):374-5. PubMed ID: 12408741
[TBL] [Abstract][Full Text] [Related]
5. Virulizin, a novel immunotherapy agent, stimulates TNFalpha expression in monocytes/macrophages in vitro and in vivo.
Li H; Cao MY; Lee Y; Benatar T; Lee V; Feng N; Gu X; Liu P; Jin H; Wang M; Der S; Lightfoot J; Wright JA; Young AH
Int Immunopharmacol; 2007 Oct; 7(10):1350-9. PubMed ID: 17673150
[TBL] [Abstract][Full Text] [Related]
6. Macrophages play a critical role in the anti-tumor activity of Virulizin.
Du C; Feng N; Jin H; Lee V; Wang M; Wright JA; Young AH
Int J Oncol; 2003 Nov; 23(5):1341-6. PubMed ID: 14532975
[TBL] [Abstract][Full Text] [Related]
7. Virulizin induces production of IL-17E to enhance antitumor activity by recruitment of eosinophils into tumors.
Benatar T; Cao MY; Lee Y; Li H; Feng N; Gu X; Lee V; Jin H; Wang M; Der S; Lightfoot J; Wright JA; Young AH
Cancer Immunol Immunother; 2008 Dec; 57(12):1757-69. PubMed ID: 18351336
[TBL] [Abstract][Full Text] [Related]
8. Virulizin, a novel immunotherapy agent, activates NK cells through induction of IL-12 expression in macrophages.
Li H; Cao MY; Lee Y; Lee V; Feng N; Benatar T; Jin H; Wang M; Der S; Wright JA; Young AH
Cancer Immunol Immunother; 2005 Nov; 54(11):1115-26. PubMed ID: 15891881
[TBL] [Abstract][Full Text] [Related]
9. NK cell activation and tumor infiltration are involved in the antitumor mechanism of Virulizin.
Cao MY; Lee Y; Feng N; Li H; Du C; Miao D; Li J; Lee V; Jin H; Wang M; Gu X; Wright JA; Young AH
Cancer Immunol Immunother; 2005 Mar; 54(3):229-42. PubMed ID: 15378281
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of Virulizin in patients with pancreatic cancer.
Warner E; Weinroth J; Chang S; MacDonald M; Strauss B
Clin Invest Med; 1994 Feb; 17(1):37-41. PubMed ID: 8174313
[TBL] [Abstract][Full Text] [Related]
11. Virulizin(R) - A review of its antineoplastic activity.
Ferdinandi ES; Braun DP; Liu C; Zee BC; Ely G
Expert Opin Investig Drugs; 1999 Oct; 8(10):1721-1735. PubMed ID: 11139822
[TBL] [Abstract][Full Text] [Related]
12. Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer.
Iwanski GB; Lee DH; En-Gal S; Doan NB; Castor B; Vogt M; Toh M; Bokemeyer C; Said JW; Thoennissen NH; Koeffler HP
Br J Pharmacol; 2010 Jun; 160(4):998-1007. PubMed ID: 20590594
[TBL] [Abstract][Full Text] [Related]
13. Synergistic activity of troxacitabine (Troxatyl) and gemcitabine in pancreatic cancer.
Damaraju VL; Bouffard DY; Wong CK; Clarke ML; Mackey JR; Leblond L; Cass CE; Grey M; Gourdeau H
BMC Cancer; 2007 Jul; 7():121. PubMed ID: 17608948
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine.
Kimura K; Sawada T; Komatsu M; Inoue M; Muguruma K; Nishihara T; Yamashita Y; Yamada N; Ohira M; Hirakawa K
Clin Cancer Res; 2006 Aug; 12(16):4925-32. PubMed ID: 16914581
[TBL] [Abstract][Full Text] [Related]
15. Escin augments the efficacy of gemcitabine through down-regulation of nuclear factor-κB and nuclear factor-κB-regulated gene products in pancreatic cancer both in vitro and in vivo.
Wang YW; Wang SJ; Zhou YN; Pan SH; Sun B
J Cancer Res Clin Oncol; 2012 May; 138(5):785-97. PubMed ID: 22270965
[TBL] [Abstract][Full Text] [Related]
16. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer.
Banerjee S; Zhang Y; Ali S; Bhuiyan M; Wang Z; Chiao PJ; Philip PA; Abbruzzese J; Sarkar FH
Cancer Res; 2005 Oct; 65(19):9064-72. PubMed ID: 16204081
[TBL] [Abstract][Full Text] [Related]
17. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.
Bianco C; Giovannetti E; Ciardiello F; Mey V; Nannizzi S; Tortora G; Troiani T; Pasqualetti F; Eckhardt G; de Liguoro M; Ricciardi S; Del Tacca M; Raben D; Cionini L; Danesi R
Clin Cancer Res; 2006 Dec; 12(23):7099-107. PubMed ID: 17145834
[TBL] [Abstract][Full Text] [Related]
18. Zyflamend suppresses growth and sensitizes human pancreatic tumors to gemcitabine in an orthotopic mouse model through modulation of multiple targets.
Kunnumakkara AB; Sung B; Ravindran J; Diagaradjane P; Deorukhkar A; Dey S; Koca C; Tong Z; Gelovani JG; Guha S; Krishnan S; Aggarwal BB
Int J Cancer; 2012 Aug; 131(3):E292-303. PubMed ID: 21935918
[TBL] [Abstract][Full Text] [Related]
19. Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts.
Larbouret C; Robert B; Bascoul-Mollevi C; Penault-Llorca F; Ho-Pun-Cheung A; Morisseau S; Navarro-Teulon I; Mach JP; Pèlegrin A; Azria D
Ann Oncol; 2010 Jan; 21(1):98-103. PubMed ID: 19889608
[TBL] [Abstract][Full Text] [Related]
20. [Experimental study of the function and mechanism combining dihydroartemisinin and gemcitabine in treating pancreatic cancer].
Wang SJ; Sun B; Pan SH; Chen H; Kong R; Li J; Xue DB; Bai XW; Jiang HC
Zhonghua Wai Ke Za Zhi; 2010 Apr; 48(7):530-4. PubMed ID: 20646665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
